Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 dose-finding study in resistant hypertension
2021-005738-41Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xxb750 in resistant hypertension (RH) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean 24-hour systolic blood pressure at Week 12. Started Aug 2022; status: active.
02
Drugs
xxb750
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on 2021-005738-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005738-41.